Oral steroid contraception

Women's Health

Volumn 11, Issue 6, 2015, Pages 743-748

  Sech, Laura A ^a   Mishell, Daniel R ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

birth control; cancer risk; novel contraception; progestins; steroid contraception; venous thromboembolism

Indexed keywords

CYPROTERONE ACETATE; DESOGESTREL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GESTODENE; MESTRANOL PLUS NORETYNODREL; NORETYNODREL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PREGNANE DERIVATIVE; SPIRONOLACTONE;

ARTERY THROMBOSIS; ARTICLE; BIRTH CONTROL; CANCER RISK; CEREBROVASCULAR ACCIDENT; DRUG FORMULATION; EVIDENCE BASED MEDICINE; FAMILY PLANNING; FEMALE; FIRST PASS EFFECT; HUMAN; ORAL CONTRACEPTION; OVIDUCT; RISK BENEFIT ANALYSIS; RISK FACTOR; UTERINE CERVIX MUCUS; UTERUS CAVITY; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; PROCEDURES;

CONTRACEPTIVES, ORAL, HORMONAL; ESTROGENS; FAMILY PLANNING SERVICES; FEMALE; HUMANS; PROGESTINS;

EID: 84952045949     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.15.82     Document Type: Article

References (33)

1. Jones J, Mosher W, Daniels K. Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995. Natl Heath Stat. Rep. 60, 1-25 (2012).
2. Christin-Maitre S. History of oral contraceptive drugs and their use worldwide. Best Pract. Res. Clin. Endocrinol. Metab. 27(1), 3-12 (2013).
3. Trussell J. Contraceptive failure in the United States. Contraception 83(5), 397-404 (2011).
4. Edelman A, Cherala G, Stanczyk F. Metabolism and pharmacokinetics of contraceptive steroids in obese women: A review. Contraception 82(4), 314-323 (2010).
5. Stanczyk F. All progestins are not created equal. Steroids 68(10-13), 879-890 (2003).
6. Bitzer J. Statement on combined hormonal contraceptives containing third or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism. J. Fam. Plann. Reprod. Health Care 39(3), 156-159 (2013).
7. Wu CQ, Grandi SM, Filion KB, Abenhaim HA, Joseph L, Eisenberg MJ. Drosperinone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: A systematic review. BJOG 120(7), 801-811 (2013).
8. Willis SA, Kuehl TJ, Spiekerman M, Sulak PJ. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 74(2), 100-103 (2006).
9. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ. Trends in the incidence of venour thromboembolism during pregnancy or postpartum: A 30-year population based study. Ann. Intern. Med. 143(10), 697-706 (2005).
10. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drosperinone-containing oral contraceptive:final results from the European Active Surveillance study on oral contraceptives based on 142,475 women-years of observation. Contraception 75(5), 344-354 (2007).
11. Heinemann LA, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception 75(5), 328-336 (2007).
12. Gertsman BB, Piper JM, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am. J. Epidemiol. 133(1), 32-36 (1991).
13. Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker J. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: A meta-analysis. BMJ 345, e4944 (2012).
14. Grimes DA, Lopez LM, O'Brien PA, Raymond EG. Progestin-only pills for contraception. Cochrane Database Syst. Rev. 11, CD007541 (2013).
15. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. BMJ 298(6667), 165-168 (1989).
16. WHO Techinical Report Serie. Cardiovascular disease and steroid hormone Contraception 877, i-vii, 1-89 (1998).
17. Hannaford PC, Croft PR, Kay CR. Oral contraception and stroke. Evidence from the Royal College of General Practitioners' Oral Contraception Study. Stroke 25(5), 935-942 (1994).
18. Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK. Stroke in users of low-dose oral contraceptives. N. Engl. J. Med. 335(1), 8-15 (1996).
19. Schwartz SM, Siscovick DS, Longstreth WT et al. Use of low-dose oral contraceptives and stroke in young women. Ann. Intern. Med. 127(8 Pt 1), 596-603 (1997).
20. US Medical Eligibility Criteria for Contraceptive Use. Adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition (2010). http://www.cdc.gov
21. US Selected Practice Recommendations for Contraceptive Use. Adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, (2nd Edition) (2013). www.cdc.gov
22. Mishell DR Jr. Noncontraceptive health benefits of oral steroidal contraceptives. Am. J. Obstet. Gynecol. 142(6 Pt 2), 809-816 (1982).
23. Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am. J. Obstet. Gynecol. 190(Suppl. 4), S5-S22 (2004).
24. Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ 340, c927 (2010).
25. Vessey M, Yeates D. Oral contraceptive use and cancer: final report from the Oxford Family Planning Association contraceptive study. Contraception 88(6), 678-683 (2013).
26. Marchbanks PA, Mcdonald JA, Wilson HG et al. Oral contraceptives and the risk of breast cancer. N. Engl. J. Med. 346(26), 2025-2032 (2002).
27. Marchbanks PA, Curtis KM, Mandel MG et al. Oral contraceptive formulation and risk of breast cancer. Contraception 85(4), 342-350 (2012).
28. Cibula D, Zikan M, Dusek L, Majek O. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: A meta-analysis. Expert Rev. Anticancer Ther. 11(8), 1197-1207 (2011).
29. Micks E, Jensen JT. Estradiol valerate and dienogest: A novel four-phasic oral contraceptive effective for pregnancy prevention and treatment of heavy menstrual bleeding. Women's Health 7(5), 513-524 (2011).
30. Micks EA, Jensen JT. Treatment of heavy menstrual bleeding with the estradiol valerate and dienogest oral contraceptive pill. Adv. Ther. 30(1), 1-13 (2013).
31. Burke A. Nomegestrol acetate-17b-estradiol for oral contraception. Patient Prefer. Adherence 7, 607-619 (2013).
32. Bennink HJ, Skouby S, Bouchard P, Holinka CF. Ovulation inhibition by estetrol in an in vivo model. Contraception 77(3), 186-190 (2008).
33. Visser M, Bennink H. Clinical applications for estetrol. J. Steroid Biochem. Mol. Biol. 114(1-2), 85-89 (2009).